Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEUROBID

Financiado

Cerrado

Neuroscience on Barriers in Development

Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to €386 billion (1). Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe’s total d... ver más

31/12/2013

MHH

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-12-31 No tenemos la información de la convocatoria

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

MHH

0.00€ | Lider

UOXF

N.D. | Participante

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Ctrl-BBB Blood brain barrier from molecular mechanisms to interventi... 2M€ Cerrado

BBBARRIER Mechanisms of regulation of the blood brain barrier towards... 2M€ Cerrado

RTI2018-097038-B-C22 PLATAFORMAS MICROFISIOLOGICAS IN VITRO PARA LA MIMETIZACION... 70K€ Cerrado

NCBio Unlocking excellence in research and innovation in neurobiol... 2M€ Cerrado

BrainGate Illuminating body-brain communication channels at the choroi... 1M€ Cerrado

JUSTBRAIN Blood brain barrier junctions as targets for paracellular dr... 4M€ Cerrado

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to €386 billion (1). Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe’s total disease burden (1). In the treatment of neurological disease, the blood brain barrier (BBB) still represents an obstacle for the delivery of drugs to the brain and thus a major challenge for the development of therapeutic regimens. Understanding the molecular basis and functioning of the BBB in health and disease, including transport mechanisms across the BBB, therefore holds significant potential for future strategies to prevent and ameliorate neurological disease. Recent research indicates that some neurological disorders have a developmental etiologic component. The major goal of the NEUROBID project is thus to understand the molecular mechanisms and function of the BBB in health and disease both in the developing brain and the adult central nervous system. With an interdisciplinary consortium from the fields of developmental neurobiology and BBB research, NEUROBID aims to (i) understand the involvement of normal and disturbed BBB function in normal and abnormal brain development and (ii) to develop novel strategies for drug delivery to the brain. Unique transport mechanisms across the BBB will be used to target potential therapeutic macromolecular and cellular agents specifically to the brain barriers and transport them into the brain. The main target disorders of NEUROBID are non-inherited neurodevelopmental disorders arising from perinatal adverse exposure, such as cerebral palsy, and classic adult neurological disorders such as multiple sclerosis and stroke. In the long term, NEUROBID hopes to pave the way for new treatment strategies and thus reduce the economic and social burden of neurological disease. 1. Olesen J, et al. Consensus document on European brain research. J Neurol Neurosurg Psychiatry 2006;77 Suppl 1:i1-49.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores